Melis M - Search Results

1

Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy.

Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Konijnenberg M, et al. Among authors: melis m. J Nucl Med. 2007 Jan;48(1):134-42. J Nucl Med. 2007. PMID: 17204710 Free article.

2

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Rolleman EJ, et al. Among authors: melis m. Eur J Nucl Med Mol Imaging. 2010 May;37(5):1018-31. doi: 10.1007/s00259-009-1282-y. Epub 2009 Nov 14. Eur J Nucl Med Mol Imaging. 2010. PMID: 19915842 Review.

3

Dynamic and static small-animal SPECT in rats for monitoring renal function after 177Lu-labeled Tyr3-octreotate radionuclide therapy.

Melis M, de Swart J, de Visser M, Berndsen SC, Koelewijn S, Valkema R, Boerman OC, Krenning EP, de Jong M. Melis M, et al. J Nucl Med. 2010 Dec;51(12):1962-8. doi: 10.2967/jnumed.110.080143. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078795 Free article.

4

Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.

Melis M, Valkema R, Krenning EP, de Jong M. Melis M, et al. J Nucl Med. 2012 May;53(5):749-53. doi: 10.2967/jnumed.111.098665. Epub 2012 Apr 10. J Nucl Med. 2012. PMID: 22496587 Free article.

5

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M. Melis M, et al. Q J Nucl Med Mol Imaging. 2007 Dec;51(4):324-33. Q J Nucl Med Mol Imaging. 2007. PMID: 17923824 Free article.

6

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.

Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Melis M, et al. Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1136-43. doi: 10.1007/s00259-005-1793-0. Epub 2005 May 24. Eur J Nucl Med Mol Imaging. 2005. PMID: 15912401

7

Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.

de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, Gekle M, Willnow TE, Walrand S, Jamar F, Pauwels S. de Jong M, et al. Among authors: melis m. J Nucl Med. 2005 Oct;46(10):1696-700. J Nucl Med. 2005. PMID: 16204720 Free article.

8

Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.

de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, de Jong M. de Visser M, et al. Among authors: melis m. J Nucl Med. 2007 Jan;48(1):88-93. J Nucl Med. 2007. PMID: 17204703 Free article.

9

From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging.

Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, Krenning EP, de Jong M. Forrer F, et al. Among authors: melis m. Cancer Biother Radiopharm. 2007 Feb;22(1):40-9. doi: 10.1089/cbr.2006.353. Cancer Biother Radiopharm. 2007. PMID: 17627412

10

Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.

Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, de Jong M. Müller C, et al. Among authors: melis m. Cancer Biother Radiopharm. 2007 Feb;22(1):151-9. doi: 10.1089/cbr.2007.309. Cancer Biother Radiopharm. 2007. PMID: 17627424

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,103 results

Search Page

Filters